Leading a new era in radiopharmaceuticals

Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.

Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline

Clinical Pipeline

One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally.

See Pipeline  

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix® and Gozellix®

Illuccix® and Gozellix®

Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia.

Illuccix® and Gozellix®  

Learn more about Telix’s Phase III prostate cancer therapy trial.

Learn more

ProstACT Global

Learn more about Telix’s Phase III prostate cancer therapy trial.

Learn more  

Latest News

See all

Telix Appoints David Gill as Non-Executive Director

Telix today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill is expected to be appointed Chair, succeeding Dr. Mark Nelson who will remain on the Board as a…

Read more

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

Read more